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Growth of tumors induced by Rous sarcoma virus (RSV) is controlled by alleles at the major histocompatibility complex
locus in chickens, indicating that immunological host defense mechanisms play a major role. We show here that the
resistance phenotype of CB regressor chickens can be partially reverted by treating the animals with a monoclonal antibody
that neutralizes the major serotype of chicken type I interferon, ChIFN-a. Injection of recombinant ChIFN-a into susceptible
CC progressor chickens resulted in a dose-dependent inhibition of RSV-induced tumor development. This treatment was not
effective, however, in CC chickens challenged with a DNA construct expressing the v-src oncogene, suggesting that the
beneficial effect of type I interferon in this system resulted from its intrinsic antiviral activity and probably not from indirect
immunmodulatory effects. By contrast, recombinant chicken interferon-g strongly inhibited tumor growth when given to CC
chickens that were challenged with the v-src oncogene, indicating that the two cytokines target different steps of tumor
development. © 1999 Academic Press
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The contribution of interferons (IFNs) to the regression
f tumors is not well understood. Early results with crude
reparations of type I IFN suggested formidable activity
gainst various tumors in mice and humans (Strander,
986; Gresser and Bourali, 1970). However, systematic
linical studies with purified preparations of human
FN-a failed to confirm such activity against many impor-
ant tumors, with the notable exception of several forms
f leukemias in humans (for review see Ezaki, 1996) in
hich IFN-a therapy proved to be effective. Recombinant
FN-g exhibited antitumor activity in several experimental
ettings in mice (Fujiwara and Hamaoka, 1996; Sveinb-
ornsson et al., 1998; Xu et al., 1996; Mao et al., 1995).
owever, a recent placebo-controlled clinical trial with
ecombinant human IFN-g failed to confirm antitumor
ctivity of this cytokine in metastatic renal cell carcinoma
Gleave et al., 1998). Collectively, these findings illustrate
hat the molecular basis of the antitumor activity of IFNs
s currently not understood well enough.
1 To whom correspondence and reprint requests should be ad-
ressed at Department of Virology, University of Freiburg, Hermann
erder-Strasse 11, D-79104 Freiburg, Germany. Fax: 149-761-203-6562.
-mail: staeheli@ukl.uni-freiburg.de. f
85A distinct feature of Rous sarcoma virus (RSV)2-in-
uced tumors of chickens is that they are induced by a
eplication-competent retrovirus. Since IFNs are strong
ntiviral agents, one might assume that RSV-induced
umors should respond particularly well to IFN therapy.
owever, due to the fact that the genes for chicken IFNs
ave been cloned only recently (Sekellick et al., 1994;
chultz et al., 1995a,b; Sick et al., 1996; Digby and Lo-
enthal, 1995; Weining et al., 1996), pure IFN prepara-
ions had previously not been available so that the role of
hese cytokines in the host defense against RSV-induced
umors could not be investigated. The CB (B12/B12) and
C (B4/B4) congenic lines of chickens have been studied
xtensively with respect to resistance to progressive
rowth of tumors induced by RSV (for review see Plachy´
t al., 1989, 1992). When challenged with the Prague
train of RSV tumors rapidly develop in CC “progressor”
hickens, whereas growth of RSV-induced tumors is
trongly restricted in CB “regressor” chickens. Cloned
TR/v-src/LTR proviral DNA that codes for the v-src on-
oprotein is also tumorigenic in chickens. The tumor
rowth restriction patterns in progressor and regressor
hickens are similar irrespective of whether the sarco-
as are induced by replication-competent RSV or by
2 Abbreviations used: RSV, Rous sarcoma virus; LTR, long-terminal
epeat; MHC, major histocompatibility complex; ChIFN, chicken inter-
eron.
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86 PLACHY´ ET AL.-src proviral DNA, although the former tumors develop
uch faster in CC chickens (Svoboda et al., 1992). The
ritical role of alleles at the major histocompatibility
omplex (B locus) in resistance against these tumors
as formally proven by genetic experiments using ap-
ropriate backcross populations of chickens, suggesting
hat an immune-based mechanism of tumor regression
s at work in this system (Plachy´ et al., 1994; Svoboda et
l., 1996). CC chickens are immunocompetent but their
pecific response to RSV antigens is low due to the lack
f appropriate peptide motifs that would bind to the B4
olecules. By contrast, the B12 molecule encoded by the
HC allele of CB chickens can bind and present RSV
eptides (Kaufman et al., 1995).
We used a neutralizing monoclonal antibody to the
ajor serotype of chicken type I IFN (ChIFN-a) to inves-
igate the role of this cytokine in the resistance of CB
hickens toward RSV-induced disease. By treating dis-
ase-prone CC chickens with recombinant ChIFN-a and
hIFN-g we further evaluated the beneficial effects of
hese cytokines on the development of RSV- and v-src
ncogene-induced tumors. Our results indicate that the
rominent antitumor effect of ChIFN-a in this system is
argely due to its potent antiviral activity. ChIFN-g seems
o act by an independent mechanism, as it delayed the
ormation in CC chickens of v-src oncogene-induced
umors that were not responsive to ChIFN-a treatment.
RESULTS
esistance of CB chickens to RSV-induced tumors is
eakened by antibodies that neutralize ChIFN-a
Infection of CB regressor chickens with RSV results in
nitial tumor growth that rapidly becomes restricted by
he host immune response. Tumor size usually does not
xceed 100 mm2 in these animals at any time postinfec-
ion (Plachy´ et al., 1994). Maximal tumor size is reached
bout 3 weeks after RSV challenge and the tumors dis-
ppear quickly thereafter. To evaluate the role of endog-
nous type I IFN in this resistance, we treated six CB
hickens with monoclonal antibody 8A9 that selectively
eutralizes ChIFN-a, which represents the predominant
erotype of virus-induced chicken IFN (Sick et al., 1998).
control group of eight animals received equivalent
mounts of irrelevant antibodies. Antibody therapy was
tarted 3 days before RSV infection and was continued
ntil 20 days postinfection. By this time all monoclonal
ntibody 8A9-treated animals had developed fairly large
umors with a mean size of about 240 mm2 (Fig. 1). The
umors of control antibody-treated animals were much
maller at this time point (mean size 105 mm2) (Fig. 1).
he tumors of both groups of chickens regressed quickly
uring the following weeks. Since antibody administra-
ion was stopped on postchallenge day 20 due to short-
ge of purified protein, it remains unclear whether the
eginning of tumor regression in the antibody-treated tnimals at this same time point was coincidential or
hether it was due to rising IFN levels. Despite this
bvious difficulty, the results of this experiment clearly
ndicated that endogenous IFN played a role in tumor
rowth restriction of CB chickens.
hIFN-a inhibits the replication of RSV in cultured
mbryo fibroblasts from CB and CC chickens
The results of the above-described IFN depletion ex-
eriment did not distinguish between a direct antiviral
ffect of IFN on RSV replication and indirect inhibitory
ffects due to an immunostimulatory activity of this cy-
okine. We therefore measured whether ChIFN-a can
nhibit the replication of our strain of RSV in cell culture.
xperiments with cultures of secondary embryo cells
rom CB chickens clearly demonstrated that this was the
ase. IFN treatment of these cells reduced RSV titers
bout 25-fold (Fig. 2). Interestingly, ChIFN-a exhibited a
omparably potent antiviral effect toward RSV in cells
rom CC chickens (Fig. 2) that fail to restrict virus-induced
umor formation in vivo.
reatment of CC progressor chickens with ChIFN-a
esults in dose-dependent inhibition of RSV-induced
umor development
In contrast to the CB regressor line, CC progressor
hickens develop rapidly growing tumors following RSV
nfection. Within 45 to 50 days postinfection, 50% of
nfected CC chickens usually die from these tumors,
hich typically have reached a size of about 2000 mm2
y that time. The efficacy of ChIFN-a toward RSV in
ultured cells suggested that RSV-infected CC progres-
or chickens might benefit from an in vivo therapy with
FIG. 1. In vivo neutralization of ChIFN-a with monoclonal antibody
A9 stimulates growth of RSV-induced tumors in CB regressor chick-
ns. Groups of 10-week-old chickens received repeated injections of
ither monoclonal antibody 8A9 (triangles; six animals) or control an-
ibody (circles; eight animals). Development of tumors was monitored
or 42 days and the mean tumor size was calculated. Antibody treat-
ent was started 3 days before RSV infection and continued until 20
ays postinfection.his cytokine.
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87INHIBITION OF RSV BY INTERFERONSince it was unclear whether Escherichia coli-pro-
uced ChIFN-a was active in vivo, we performed a pilot
xperiment in which we measured whether intravenous
njection of this material would result in enhanced ex-
ression of the IFN-inducible Mx gene. An adult chicken
as given 106 IU/kg of purified ChIFN-a by the intrave-
ous route. Blood was taken 8 h later and RNA was
solated from the PBMCs. RNA from PBMCs of an un-
reated chicken served as negative control. Northern blot
nalysis showed clearly detectable levels of Mx tran-
cripts in the RNA sample from the IFN-treated animal
ut not in the sample from the untreated control animal
Fig. 3), indicating that our preparation of ChIFN-a was
lso active in vivo.
To determine whether RSV-induced tumor develop-
ent in CC chickens might be influenced by ChIFN-a, we
reated the chickens with a low-dose IFN regimen start-
ng at 3 days prior to challenge with 100 focus-forming
nits (FFU) of RSV until day 30 postinfection. The animals
eceived injections of 104 IU of ChIFN-a every second
ay. Tumor development was significantly delayed in
FN-treated animals compared to the untreated control
hickens (Fig. 4A). Maximal differences in the mean
umor sizes were observed between 35 and 42 days
ostinfection. IFN treatment also had a positive effect on
he survival of the chickens. At 52 days postinfection, 10
f the 11 untreated chickens were dead. By contrast, all
IFN-treated animals were still alive at this time point
Fig. 4B). Although the beneficial effect of the IFN therapy
as clear-cut in this experiment, it failed to prevent lethal
isease in the treated animals.
In a second experiment we evaluated whether in-
reased doses of IFN would influence the results. For
his experiment, we further lowered the virus challenge
ose to 10 FFU per animal. Increasing the ChIFN-a dose
rom 104 to 105 or 106 IU per injection resulted in a
ose-dependent reduction of the mean tumor size (Fig.
FIG. 2. Inhibition of RSV replication by ChIFN-a in cultured chicken
mbryo fibroblasts of CC and CB chickens. Monolayers of cells from
C and CB chickens were treated with 100 IU/ml of ChIFN-a or plain
edium before infection with RSV at a multiplicity of 0.1 FFU. Three
ays later, the viral titers in the supernatants were determined.C). The mean survival time of the chickens was also cffected positively. One of the eight animals that received
05 IU and two of the six animals that received 106 IU of
hIFN-a per injection survived until the termination of
he experiment on day 120 postinfection (Fig. 4D). By this
ime their tumors had disappeared.
hIFN-a fails to inhibit tumor induction by the v-src
ncogene in CC chickens
The therapeutic effect of IFN could have resulted from
nhibition of RSV replication or could have been due to a
timulatory effect of IFN on the poorly performing im-
une system of CC chickens. If the latter effect was
perative, the IFN therapy should be equally beneficial
gainst tumors induced by either RSV or v-src DNA. We
herefore challenged new groups of CC chickens with a
NA construct that codes for this viral oncogene product
nd subjected one group of eight animals to high-dose
hIFN-a therapy. No beneficial effect of the repeated
njections of cytokine was observed under these exper-
mental conditions. Actually, in this experiment the IFN-
reated chickens developed slightly larger tumors than
ontrol animals (Fig. 5). These results suggest that the
ntitumor effect of ChIFN-a in this system resulted from
ts potent antiviral activity rather than from immunomodu-
atory effects.
hIFN-g inhibits v-src oncogene-induced tumor
ormation in CC chickens
Since ChIFN-g is a poor antiviral agent but a very
otent activator of macrophages (Weining et al., 1996), it
as of interest to determine whether it might exhibit
ntitumor activity in vivo. We have previously shown that
urified recombinant ChIFN-g is biologically active,
hereas a variant protein lacking the C-terminal 18
mino acids is not (Puehler et al., 1998). We therefore
reated groups of eight CC progressor chickens with
ull-length or truncated forms of ChIFN-g, while a control
roup received no treatment. Three days after the first
njections, all animals were challenged with v-src DNA
nd tumor development was monitored. Figure 6 shows
hat tumor growth was very slow in chickens that were
FIG. 3. Intravenous injection of ChIFN-a results in enhanced expres-
ion of the Mx gene in PBMCs. An adult animal was given a single
ntravenous injection of 106 IU/kg of ChIFN-a (1), while a control
nimal was left untreated (2). Eight hours later, blood was taken from
oth animals, RNA was isolated from PBMCs and analyzed for the
resence of transcripts derived from the Mx gene by Northern blotting.
eprobing of the membrane with radiolabeled chicken actin cDNA
onfirmed that equal amounts of RNA were loaded into the two lanes.
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88 PLACHY´ ET AL.reated with full-length ChIFN-g and that the mean tumor
ize did not exceed 66 mm2 during the complete obser-
ation period of 85 days. By contrast, in chickens treated
ith inactive mutant ChIFN-g tumors developed nearly
s quickly as in the untreated control animals, and they
eached sizes of 200 mm2 or more within about 7 weeks.
FIG. 4. Effect of ChIFN-a treatment on tumor growth and survival of
reated with 104 IU of ChIFN-a per injection (triangles) and 11 untreate
hIFN-a, these animals were challenged with 100 FFU of RSV. ChIFN-a
C and D), the chickens were treated with 104 IU (triangles; eight anim
nimals) per injection. Eight untreated chickens served as controls (c
hallenged with 10 FFU of RSV. ChIFN-a treatment was continued until d
FIG. 5. No effect of ChIFN-a on tumor growth induced by a LTR/v-
rc/LTR DNA construct in CC chickens. Control chickens (circles; eight
nimals) and chickens treated with 106 IU of ChIFN-a per injection
triangles; eight animals) were challenged by subcutaneous inocula-
ions of 0.6 mg of oncogenic LTR/v-src/LTR DNA 3 days postonset of
hIFN-a treatment. IFN treatment was continued until day 30 postin-tection. Mean tumor sizes of the chickens are plotted.e controlled for the remote possibility that the LTR,
-src, LTR construct had formed tumors because it was
ackaged by an endogenous retrovirus by performing
outhern blot analysis of DNA samples from several
umors. This analysis yielded no evidence for the pres-
nce of avian leukemia virus and no evidence for v-src
ncogene amplification or rearrangements (data not
hown). Thus, unlike ChIFN-a, recombinant ChIFN-g ex-
ibited antitumor activity that cannot be simply due to
nhibition of virus replication.
DISCUSSION
Previous genetic analyses had shown that the robust
esistance of CB chickens to RSV-induced tumors results
rom a strong immunological response of these animals
gainst the v-src oncogene and that the B12 allele at the
HC locus is of critical importance in this defense pro-
ess (Plachy´ et al., 1994; Svoboda et al., 1996). It re-
ained unclear, however, whether IFNs and other fac-
ors of the innate immune system also played a role. By
njecting a monoclonal antibody that neutralizes ChIFN-a
nto RSV-infected CB chickens we obtained clear evi-
ence that this cytokine contributes to the tumor resis-
ance phenotype: in treated animals the initial growth of
SV-induced tumors was much more rapid than in con-
fected CC chickens. In a first experiment (A and B), 9 chickens were
ens served as controls (circles). Three days after the first injection of
ent was continued until day 30 postinfection. In a second experiment
05 IU (squares; eight animals), or 106 IU of ChIFN-a (rhombuses; six
. Three days after the first injection of ChIFN-a, these animals were
ostinfection. Mean tumor size and survival of the chickens are plotted.RSV-in
d chick
treatm
als), 1
ircles)rol chickens that received irrelevant antibodies.
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89INHIBITION OF RSV BY INTERFERONA priori we could not distinguish between the possi-
ility that the detrimental effect of the neutralization of
irus-induced IFN-a was due to enhanced replication of
SV in the antibody-treated animals and the possibility
hat the immune system of the IFN-a-depleted animals
as compromised and failed to mount a quick and ef-
ective antitumor response. If the former possibility was
orrect, IFN-a should block RSV replication in cell culture
nd it should also have a beneficial effect when applied
o CC chickens that cannot control RSV-induced tumors
ufficiently well by immunological means. In agreement
ith these predictions we found that the infection of
hicken embryo cells from CB and CC chickens was
mpaired to similar degrees when the cultures were
reated with ChIFN-a and that treatment of RSV-infected
C chickens with recombinant ChIFN-a strongly delayed
umor growth and resulted in prolonged survival of the
reated animals. If the second possibility was correct and
f ChIFN-a indeed acted against RSV-induced tumors via
nonspecific stimulation of the immune system, it would
e expected that ChIFN-a is also effective against ex-
erimental tumors induced by the isolated v-src onco-
ene. Contrary to this prediction we found that tumors
esulting from injection of RSV DNA could not be treated
uccessfully with ChIFN-a. Taken together these results
trongly suggested that the antitumor effect of ChIFN-a
n this system resulted mostly if not exclusively from
ts antiviral activity. In sharp contrast to the results
ith ChIFN-a, we found that ChIFN-g was active
FIG. 6. Inhibition by ChIFN-g of v-src oncogene-induced tumor
rowth in CC chickens. Control chickens (circles; eight animals), chick-
ns treated with 10 mg of ChIFN-g (triangles; eight animals), or chick-
ns treated with 10 mg of a biologically inactive mutant form of ChIFN-g
squares; eight animals) were challenged by subcutaneous inocula-
ions of 0.6 mg of oncogenic LTR/v-src/LTR DNA 3 days postonset of
hIFN-g treatment. Treatment was continued until day 53 postinfection.
ean tumor sizes of the chickens are plotted.gainst tumors of CC chickens that were induced by che v-src oncogene. Thus, the antitumor activities of
he two types of IFN appeared to be complementary in
his system.
A picture thus emerges that shows that there are at
east two lines of defense against RSV-induced tumors in
hickens. The first line of defense is based on virus-
nduced IFN, which may be critical at an early stage after
nfection and which may limit virus spread before the
econd line of defense, the specific immune response
gainst the intruder, is generated. In chickens of strains
C and CB the first line of defense appears to be in place
ut the physiological levels of virus-induced IFN proba-
ly cannot block RSV replication well enough to prevent
umor growth and disease in CC chickens that fail to
ount an effective immune response against RSV. As
redicted in this model, we found that when the first line
f defense was enhanced by supplying large amounts of
ecombinant ChIFN-a, we could delay tumor growth
ather effectively in CC chickens. The complementary
xperiment also worked: when the first line of defense
as weakened by neutralizing virus-induced IFN by
onoclonal antibody 8A9 in CB chickens, it took these
nimals longer to get the growing tumor under control.
he second line of defense is well developed in CB
hickens that carry the B12 allele at the MHC locus,
hereas it is very weak in CC chickens that carry the B4
llele. Our successful inhibition of v-src oncogene-in-
uced tumor growth in CC chickens with recombinant
hIFN-g indicates that the poor immunological defense
f these animals can be strengthened by this cytokine.
he presumably complex immunological mechanisms
ehind the observed enhanced performance of IFN-g-
reated CC chickens remain to be elucidated.
Considering the fact that IFN-a is fairly effective
gainst several tumors in humans (Strander, 1986; Ezaki,
996) and the fact that clinical trials with IFN-g yielded
isappointing results (Gleave et al., 1998), our findings
ith v-src oncogene-induced tumors in chickens that
evealed exclusive therapeutic effects of IFN-g came as
surprise. Our findings are in agreement, however, with
esults of experiments in mice that lack a functional type
IFN system that suggested that the physiological role of
FN-a is restricted to antiviral defense (Mu¨ller et al.,
994). From these observations it appears that the most
pectacular therapeutic effects of IFN-a might be ob-
erved in clinical settings that involve virus-induced tu-
ors.
MATERIALS AND METHODS
nimals
Chickens of the Prague congenic lines CB (B12/B12)
nd CC (B4/B4) were used (Plachy´ et al., 1989, 1992). Both
ongenic lines were free of avian leukosis virus.
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90 PLACHY´ ET AL.SV titrations
The Prague strain of RSV subgroup C (PR-RSV-C) was
sed. Virus titers were measured by the focus assay, in
hich chicken fibroblasts were pretreated for 1 h with 10
g of polybrene per 4 ml of medium (Toyoshima and
ogt, 1969) and expressed as FFU/ml.
hallenge of chickens with RSV and tumor monitoring
Approximately 10-week-old chickens were inoculated
ubcutaneously into the left wing webs with 0.1 ml of
tock virus (usually 100 FFU) diluted in Eagle’s minimal
ssential medium containing 5% calf serum, 5% fetal
ovine serum, 10% tryptose phosphate broth, 100 IU/ml
f penicillin, and 100 mg/ml of streptomycin. The area of
umor growth in the wing web was measured by placing
ransparent foil on the tumor and tracing its contours.
he picture of the tumor was then transferred onto a
heet of millimeter paper. The tumor size was calculated
s half the sum of outer and inner regular figures fitting
he picture of the tumor (Svoboda et al., 1992).
reparation and inoculation of v-src proviral DNA
The LTR/v-src/LTR provirus used here was originally
escued from H-19 hamster tumor cells and transfected
nto Japanese quail cells (Geryk et al., 1986). The clonal
ine F6K4 of transformed quail cells was used for DNA
loning. The proviral DNA in this cell line has lost its
eplication competence due to a deletion of all viral
enes except v-src (Bodor and Svoboda, 1989). The viral
NA was released with BamHI and HindIII from lambda
6K4c1.2 (Svoboda et al., 1992) and cloned into the same
estriction sites of pUC18. Maxipreps of plasmid DNA
ere prepared by the alkaline lysis method and super-
oiled DNA was purified twice on CsCI gradients. This
NA was linearized again by BamHI and HindIII double
igestion, aliquoted (150 mg/ml) in TE buffer (10 mM Tris,
mM EDTA pH 8.0), and kept at 220°C. For each DNA
noculation a fresh aliquot was used. About 1.5 mg of
NA diluted in phosphate-buffered saline (total volume
00 ml) was inoculated subcutaneously into the left wing
eb, an amount that corresponds to about 0.6 mg of the
TR/v-src/LTR DNA fragment.
ecombinant ChIFNs
The production in E. coli and purification to near ho-
ogeneity of recombinant ChIFN-a (previously referred
o as ChIFN1 (Sick et al., 1998)) have been described
Schultz et al., 1995b). Purified ChIFN-a had a specific
ctivity of 2 3 107 IU/mg.
Histidine-tagged recombinant ChIFN-g (His-ChIFN-g)
as produced in E. coli and purified as described (Wein-
ng et al., 1996). A biologically inactive mutant form of
is-ChIFN-g that lacks the 18 C-terminal amino acidsPuehler et al., 1998) served as negative control. PhIFN-a-specific monoclonal antibody 8A9
Monoclonal antibodies were developed by immunizing
ou/c rats with recombinant ChIFN-a. Hybridomas were
elected for their ability to neutralize the antiviral activity
f ChIFN-a in cytopathic effect reduction assays. A sin-
le monoclonal antibody (8A9, rat IgG1 subclass) neu-
ralized the major serotype of chicken type I IFN
ChIFN-a, previously designated ChIFN1 (Sick et al.,
998)) but not the minor serotype (ChIFN-b, previously
esignated ChIFN2 (Sick et al., 1998)) (data not shown).
he monoclonal antibody was purified from cell culture
upernatants by affinity chromatography on protein
–Sepharose, followed by dialysis against PBS. Anti-
ody preparations were adjusted to a final concentration
f 1 mg/ml.
reatment of chickens with monoclonal antibody 8A9
CB chickens were inoculated intravenously with 50 mg
f purified monoclonal antibody 8A9 starting 3 days be-
ore challenge with RSV, and nine consecutive injections
f the same antibody dose were given in 1- to 3-day
ntervals thereafter. The last injection was given 20 days
ostchallenge. Control chickens received 50 ml of normal
abbit serum by the same regimen.
FN treatment
CC chickens were treated with recombinant ChIFN-a
y injecting 104, 105, or 106 IU by the intravenous route.
his treatment was started 3 days before challenge with
SV or v-src DNA. Altogether 20 injections were given in
- to 2-day intervals up to the 30th day postchallenge.
en-microgram samples of full-length or C-terminally
runcated His-ChIFN-g were injected intravenously. The
irst two injections were given 3 days and 6 h before
umor challenge. Altogether 19 injections were given in
- to 4-day intervals. The last injection was on day 53.
ssay for measuring the expression of the IFN-
nducible Mx gene in vivo
A single dose of 106 IU/kg of ChIFN-a was adminis-
ered intravenously to an adult chicken. A control animal
as left untreated. Eight hours later, blood was collected,
NA was prepared from the PBMCs, and samples were
ssayed by Northern blotting for transcripts of the IFN-
nducible Mx gene using a radiolabeled cDNA probe
Bernasconi et al., 1995). To confirm that similar amounts
f RNA were loaded into each lane, the blot was re-
robed with a radiolabeled actin cDNA probe (Kost et al.,
983).
ell culture assay for RSV replication inhibition
Secondary chicken embryo fibroblasts were treated
ith 100 IU/ml of ChIFN-a for 18 h before infection with
R-RSV-C at a multiplicity of 0.1 FFU. The same concen-
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91INHIBITION OF RSV BY INTERFERONration of ChIFN-a was present in the medium after the
ells had been infected. Three days after infection, the
irus yields in the supernatants were determined by a
ocus-forming assay as described (Svoboda et al., 1985).
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